Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew hip resurfacing system recall

This article was originally published in The Gray Sheet

Executive Summary

Voluntary recall announced Aug. 16 includes 185 Smith & Nephew Birmingham Hip Resurfacing System implants. The recall cites incorrect packaging by a subcontractor that resulted in different sizes of acetabular cups being mixed together. S&N says its investigation has confirmed that the problem is confined to a "small number of batches" distributed in "a number" of countries, including the United States and the United Kingdom. The system was approved by FDA in 2006 1("The Gray Sheet" May 15, 2006, p. 8)...

You may also be interested in...



FDA Okays Smith & Nephew’s Birmingham Hip, But Orders Postmarket Studies

Smith & Nephew will be the first to offer hip resurfacing in the U.S. after FDA approved the firm's Birmingham system May 9

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel